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Abstract 
Purpose: To develop and optimise sustained release (SR) matrix tablets of diltiazem hydrochloride (DHL). 
Methods: DHL tablets were prepared by direct compression and consisted of hydroxyprpoylmethyl cellulose, 
Kollidon SR and Eudragit RSPO. A 32 full factorial design was applied to study the effect of polymers used on drug 
release from the DHL. The tablets were also evaluated for physicochemical characteristics and release kinetics.  In 
vivo human volunteer studies were carried out on the optimised formulation with a commercial sustained release 
product serving as reference. 
Results: The physicochemical characteristics of all prepared tablets were satisfactory. The developed drug delivery 
system provided prolonged drug release rates over a period of 24 hours. The release profile of the developed 
formulation was described by the Higuchi model. Mean time of occurrence for maximum (peak) drug concentration 
(Tmax) was 2.05 ± 0.52  and 2.30 ± 0.57 h for the optimized and commercial formulations, respectively, while mean 
maximum concentration of drug (Cmax) was 501.74 ± 0.05 and 509.65 ± 0.06, ng/ml respectively. Good correlation 
between the dissolution profiles and bioavailability was observed using the method of linear regression analysis and 
correlation coefficient. 
Conclusion: A fair correlation between in vitro dissolution and in vivo data was found. The results obtained indicate 
successful development of a sustained release formulation of diltiazem. 
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Compressed hydrophilic matrices have become 
popular as modified release dosage forms for 
oral administration in terms of clinical efficacy 
and patient compliance [1]. Matrix system is 
often used for manufacturing sustained-release 
dosage forms easy of production [2].  
 
Diltiazem HCl is a water soluble calcium-channel 
blocker belonging to the benzothiazepine family. 
Calcium channel blockers affect the movement of 
calcium into the cells of the heart and blood 
vessels, relaxing the blood vessels and 
increasing blood supply and oxygen to the heart. 
They are generally used to treat high blood 
pressure, arrhythmia and angina pectoris [3].  
 
There are several studies where the polymer 
type, composition, and tablet characteristics have 
been studied in order to achieve desired DHL 
release profile [4-6]. Carbopols, polyvinyl alcohol, 
sodium carboxymethylcellulose, carrageenan 
and xanthan gums are among the most widely in 
this regard [7-9]. Matrix tablets can be prepared 
by wet granulation or by direct compression [10]. 
These tablets, when prepared using HPMC 
K15M CR, on contact with dissolution media or 
gastric fluids become hydrated to form a viscous 
gel layer through which drug will be released by 
diffusion and/or by erosion of the matrix [11]. 
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However, the use of only hydrophilic polymers for 
extending drug release for highly water-soluble 
drugs is limited due to rapid diffusion of dissolved 
drug through hydrophilic gel networks. For such 
highly water soluble drugs, it becomes necessary 
to incorporate another type of polymer in the 
matrix system.  
 
Among such polymers, Eudragit RLPO or RSPO 
have been used successfully to formulate 
appropriate sustained release matrix 
formulations [12-14]. The aim of the present 
study, therefore, was to design a sustained 
release matrix tablet capable of producing 20 - 
24 h sustained release of diltiazem HCl using a 
combination of hydrophobic and gelling 
hydrophilic polymer. A secondary objective was 
to evaluate the influence of polymer content and 
type as well as polymer combination on drug 






Diltiazem hydrochloride and magnesium stearate 
were received as gifts from Golden Cross 
Pharma (India). Hydroxypropyl methylcellulose 
(HPMC) K15M CR Premium and starch (Sta-RX 
1500) were obtained from Colorcon Asia Private 
Ltd. (India) while polyvinyl acetate/polyvinylpyrro-
lidone (Kollidon SR) was supplied by BASF 
(India). Eudragit RSPO and the microcrystalline 
cellulose (MCC) were purchased from Evonik 
GmbH (Germany) and Ozone® International 
(India), respectively.  
 
Preparation of diltiazem tablets 
 
All the powder materials (drug and Excipients) 
were passed through a sieve of aperture size of 
250 µm and then blended in a polybag manually. 
The blends were directly compressed (with 
compressing weight of 502 mg for tablets 
containing a single polymer and 452 mg for 
combination of polymers) on a Cadmach single 
punch tablet machine (Ahmadabad, India) using 
8 mm concave punches.  
 
Factorial design  
 
A 32 factorial design was used in this study and 
two factors evaluated, each at three levels; 
experimental trials were performed at all nine 
combinations. Combinations of polymer HPMC 
K15 CR (X1) and Eudragit RSPO (X2) were 
selected as independent variables (Table 1). 
Drug release at 18 and 20 h was selected as 
dependent variables. The data were also 
subjected to 3D response surface methodology 
to determine the influence of polymer and binder 
on dependent variables. 
 
All the batches each contained 100 mg diltiazem 
hydrochloride, 11.95 % Starch 1500, 2 % talc, 
0.39 % magnesium stearate and MCC q.s. to 
produce tablets of 452 mg weight. 
 
Table 1: Formulation variables in a 32 factorial design 
 
Level Factor 
-1 0 1 
X1: amount of HPMC K15M CR (mg) 150 170 190 
X2: amount of Eudragit RSPO (mg) 60 80 100 
 
Physical evaluation of diltiazem hydrochlo-
ride tablets 
 
Tablet hardness was determined with a 
Monsanto tablet hardness tester (Campbell 
Electronics, Mumbai, India). The hardness of 
each of 10 tablets randomly selected from each 
batch was measured and then mean and 
standard deviation evaluation while friability was 
obtained with a friabilator (Hoffmann-La Roche 
Ltd., Basel, Switzerland). The weight of ten 
tablets before and after the test, and the percent 
loss in weight recorded as friability. The drug 
content of the tablets was evaluated 
spectrophotometrically (Shimadzu, model no-
1700) at 235 nm.  
 
In vitro drug release studies  
 
In vitro drug release studies were carried out in 
900 ml of 0.1M HCl for the first 2 h using a USP 
XXII type 1 dissolution apparatus (Electrolab 
TDT-08L) at 50 rpm and 37 ± 0.5 °C. 
Immediately after, the dissolution medium 
replaced with 900 ml of phosphate buffer (pH 
6.8) that has been pre-equilibrated to 37 °C. At 
predetermined time intervals during the 
dissolution test, samples (5 ml) were withdrawn 
for assay and replaced with equivalent volume of 
fresh medium to maintain conditions. All 
dissolution studies were performed in triplicate. 
The samples were filtered, diluted appropriately 
was and then analyzed for diltiazem 
spectrophotometrically (Shimadzu, Japan) at 235 
nm. The test was performed in triplicate. 
 
Kinetic analysis of dissolution data  
 
The release data were fitted to five kinetic 
models, viz, zero-order, first-order, Higuchi, 
Korsmeyer-Peppas and Hixson-Crowell to 
determine drug release mechanism with the aid 
of Expert 7.0.3 trial software, GraphPad Instat® 
(GraphPad Software Inc., San Diego, CA).  
 
 
Baviskar et al 
Trop J Pharm Res, October 2013;12 (5): 
 
681 
In-vivo evaluation studies  
 
Bioavailability studies were carried out on the 
experimental formulation and Commercial 
formulation Diltime SR (Zydus medica, India) 
tablet which served as the reference. The human 
study was approved and carried out in 
compliance with the protocol of the institutional 
ethical committee (approval reference no. 
CPBEMV-112009 under CPU, India) following 
the guidelines for bioavailability and 
bioequivalence studies, CDSCO, DGHS, India. 
[16]. The subjects enrolled in the study were 
presented with full details of the investigation, 
both verbally and in written form, prior to 




Six healthy non-smoking adult male subjects 
between 20 and 29 years old (Mean=24.7 years, 
SD± 3.4 years) and weighing from 55 to 65 kg 
(Mean =61 kg, SD±5.1 kg)  were admitted to the 
intra-individual randomized three-period 
crossover study designed for single-dose blood 
level study. The subjects received diltiazem HCl 
in each trial period, i.e., the test formulation 
(DHE9) or Diltime SR (reference). Dosage form 
administration strictly adhered to the study 
protocol.  
 
Sample collection and analysis 
 
Blood samples (5 ml) were collected from 0 to 48 
h after administration of DHE9 and Diltime SR. 
Plasma was harvested by taking 0.5 mL of 
plasma in ria vial, added 100 µl of  0.1 N HCL, 
vortexed the vials on vortexer, then added 3 mL 
of Ethyl Acetate, again vortexed for 5 mins, then 
centrifuged the vials  in cold centrifuge for 10 min 
at 4500 rpm at 4ºC. Separated 2 mL of upper 
layer of organic solvent in vial, evaporated to 
dryness at 50 ºC under a steady stream of 
nitrogen and kept at -20 0C pending analysis by 
High pressure liquid chromatography (HPLC). 
Plasma diltiazem HCl concentration was 
determined by a HPLC method. Sample 
preparation was performed by liquid-liquid 
extraction in tert-butyl methyl ether. The organic 
solvent was evaporated and the residue 
dissolved in a mobile phase. Aliquots of 20 µL 
were injected automatically into the 
chromatograph. Separation of diltiazem was 
achieved on reversed phase (C18) column with a 
mobile phase consisting of 10 mM ammonium 
acetate: acetonitrile (55:45 v/v). Quantitation of 
diltiazem was performed by UV detector at 235 
nm.  
 
Each sample was analysed in triplicate and the 
mean computed. Pharmacokinetics parameters, 
i.e., Cmax and Tmax, were determined from  plasa 
concentration versus time data, while AUC0-t was 
calculated from the mean plasma diltiazem HCl 
concentration-time data. 
 
Stability of test formulation 
 
The optimized batch DHE9 was kept for 
accelerated stability study at 40°C/75% R.H. as 
per ICH guidelines for up to 6 months. 
Accelerated stability study samples were 
analyzed for physical appearance, drug content 
and dissolution profiles with reference to initial 




For optimization of tablet formulations and data 
analysis, software, Opti-Stat (made in-house 
version 1.0.0), was developed. The resulting data 
were fitted to OPTI-STAT and Design Expert 
7.0.3 (Stat-ease) software which analyzed 
statistically using analysis of variance (ANOVA). 
To compare the mean of all release data and to 
assess statistical differences between them, 
either single-factor analysis of variance (ANOVA) 
or unpaired two-tailed t-test was carried out at 95 
% confidence level while multiple regression 





Physical characteristics of tablets 
 
The physical appearance, hardness, friability 
and drug content were well within the prescribed 
limits (Table 2). All the physical parameters of 
the compressed tablets complied with the official 
requirements [15]. 
 
Drug release from DHL matrix tablets  
 
The presence of polyvinyl acetate/polyvinyl-
pyrrolidone (Kollidon SR) gave burst release 
profiles. Table 3 shows release profiles of RSPO-
HPMC-based formulations. RPSO and HPMC 
concentration ranges of 22.1 to 30.3 % and 33.8 
to 42.0 %, respectively, provided drug sustained 
release for over 20 h, with 90.56 ± 0.65 to 99.09 
± 0.89 drug released, irrespective of the polymer 
content. Formulation DHE9 containing optimum 
blend of the polymers, sustained drug release for 
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Variable level  
in coded form 







DHE1 -1 -1 8.3±0.4 92.32±4.20 0.63 
DHE2 -1 0 8.5±0.5 90.25±2.40 0.66 
DHE3 -1 1 8.6±0.2 96.43±5.10 0.53 
DHE4 0 -1 8.5±0.1 97.24±3.30 0.72 
DHE5 0 0 8.2±0.3 94.45±5.20 0.58 
DHE6 0 1 8.3±0.1 95.14±3.30 0.69 
DHE7 1 -1 8.3±0.2 91.45±1.50 0.59 
DHE8 1 0 8.4±0.3 93.24±2.40 0.65 
DHE9 1 1 8.5±0.4 97.32±4.20 0.61 
 
Table 3: Release of diltiazem HCl from the test formulations as per factorial design 
 
Formulation code   Time 
(h) DHE1 DHE2 DHE3 DHE4 DHE5 DHE6 DHE7 DHE8 DHE9 Diltime SR  
1 22.0 20.3 18.9 19.3 18.5 17.9 18.3 17.9 15.9 17.20  
2 32.5 30.9 25.8 27.1 25.6 25.6 29.9 29.9 25.9 20.94  
3 37.8 35.9 32.6 38.6 36.0 34.0 38.0 35.9 31.9 24.48  
4 41.2 39.2 36.8 41.9 40.3 34.3 42.9 43.2 39.2 28.15  
5 46.8 45.2 42.8 48.4 46.8 43.8 52.2 49.2 43.2 31.86  
6 54.1 51.6 46.3 51.0 49.3 45.3 56.0 53.3 48.3 35.39  
7 60.2 58.2 53.7 55.7 53.7 50.7 60.7 57.2 52.2 38.75  
8 65.8 64.1 59.1 59.0 58.8 55.8 63.4 61.1 56.1 42.52  
9 69.4 67.0 65.4 67.7 65.9 63.9 65.5 66.0 61.0 46.89  
10 73.9 71.7 68.1 71.5 69.9 65.9 71.1 70.7 65.7 50.11  
11 78.8 76.3 71.3 74.1 72.8 68.8 73.8 74.3 69.3 53.89  
12 82.6 80.6 76.3 78.3 76.8 73.8 76.3 78.0 72.0 57.24  
14 86.8 85.3 82.8 83.1 81.3 78.3 82.8 82.3 78.3 63.95  
16 93.9 92.9 89.3 88.7 87.9 84.9 87.5 86.5 82.5 71.85  
18 97.6 95.4 94.8 94.4 92.8 90.8 91.1 89.2 87.2 77.98  
20 99.1 98.5 97.9 97.5 96.5 95.5 94.8 93.6 90.6 85.69  
22       98.7 97.9 93.9 93.82  
24         98.0 99.54  
  
Drug release kinetics 
 
When the in vitro release data were subjected to 
kinetic analysis, Higuchi and Korsmeyer-Peppas 
model gave the highest correlation coefficient 
(R2) 0.996 and 0.995 and n value of 0.564, thus 
indicating that the release mechanism was mixed 
of diffusion-erosion so called anomalous drug 
diffusion. 
 
In vivo availability    
   
Drug release from DHE9 was almost similar to 
that from commercial formulation which was 
selected. Mean plasma concentration profiles of 
DHE9 and commercial formulation are presented 
in Figure 1. 
 
 
Fig 1: Mean plasma concentration of optimized 
diltiazem HCl formulation (▲) and commercial 
(reference) product (□)  
 
Both the formulations exhibited as sustained 
release in vivo. All the pharmacokinetics 
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parameters displayed in Table 4  Mean Time of 
occurrence for maximum (peak) drug 
concentration  (Tmax) was 2.05 ± 0.52 h  and 2.30 
± 0.57 h for the optimized and commercial 
formulations, respectively, while mean Maximum 
concentration of drug (Cmax) was 501.74 ± 0.05 
ng/ml and 509.65±0.06 ng/ml, respectively. 
AUC(0-∞)is an area under the drug concentration 
in plasma versus time curve. The values for 
Cmax, Tmax, AUC (0-t) and AUC (0-∞) were 
found to be comparable indicating formulation 
exhibited comparable sustained release pattern. 
 
Table 4:  Pharmacokinetic parameters of optimized 




In vitro/in vivo 
 
Correlation 
   
When the in-vitro dissolution of diltiazem HCl 
was compared with in-vivo data using the 
method of linear regression analysis, a 
correlation coefficient (r2) of 0.8551 was found, 
indicating only a fair correlation 
 
Stability of test formulation 
 
The stability of the test formulation, stored at 40 
°C/75 %RH, was monitored over a period of 6 
months as per ICH guidelines and not noticeable 
changes in its physical appearance, drug content 
and dissolution profiles were found.. Drug 
content and dissolution at the end of 24 h was 
initially found to be 97.32±4.20 and 98.0±4.30 % 
respectively while same was observed to be 
96.22±3.80 and 97±3.72 % after the period of six 




A suitable sustained release diltiazem HCl 
dosage form would not only enhance therapeutic 
efficacy and patient compliance but also produce 
more desirable blood drug levels and lower 
incidence of adverse effects.  
 
The drug content of the formulations ranged from 
90.25 ± 2.40 - 97.32 ± 4.20, indicating good 
content uniformity for some of the formulations. 
Furthermore, all the formulations showed 
satisfactory mechanical characteristics based on 
the hardness and friability data.  
 
The presence of polyvinyl acetate/polyvinylpyrro-
lidone (Kollidon SR) caused a ‘burst’ release 
phenomenon. This can be explained by the high 
water permeability of Kollidon SR while the 
presence of Eudragit RSPO and HPMC 
promoted slow release.as drug is released by 
erosion of the Eudragit matrix and swelling and 
gelling property of the HPMC. Hence, Eudragit 
RSPO and HPMC K15 M CR were selected for 
the optimization of drug release.  
 
As the concentration of Eudragit RSPO 
increased, there was decrease in dissolution rate 
due to the extremely low water solubility of 
RSPO whose hydrophobic character caused a 
delay in the penetration of dissolution medium 
into the matrix, thereby decreasing drug 
dissolution and diffusion rate. Since RSPO 
remains undissolved at various pH conditions, 
the polymer also acts as an insoluble barrier to 
the release of drug from within the matrix.   
 
Generally, the Higuchi order model gave the 
highest correlation coefficient (R2) value for the 
dissolution data. This indicates that the in vitro 
drug release pattern is not controlled by the 
amount of drug left in the tablet as dissolution 
progresses or by the disintegration of the tablet, 
but by the diffusion. Since Eudragit is also swells, 
penetration of water does occur due to polymer 
chain relaxation after prolonged contact with 
water. 
 
The Korsemeyer-Peppas release exponent (n) 
value of the optimised formulation (DHE9) is 
0.564, which indicates anomalous drug diffusion 
[7]. This is means that drug release was both by 
diffusion and erosion, and this is probably so 
because HPMC swells to form a gel through 
which the drug diffuses while the drug is also 
released by erosion of Eudragit matrix. The 
optimised formulation DHE9 showed a correlation 
coefficient of 0.9961 for the Higuchi model 
indicating a largely diffusion-dependent drug 
release. The in vitro and in vivo correlation was 





Sustatined release diltiazem HCl matrix tablet 
formulation that released drug up to 24 h has 
been developed. The tablets showed good 






C max  
(ng/ml) 
501.74±0.054 509.65±0.057 
T max (h)   2.05±0.52 2.3±0.57 
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